Developing treatments for patients with underserved CNS disorders
Bionomics is a global, clinical-stage biopharmaceutical company developing a pipeline of novel, drug candidates designed to transform the lives of patients suffering from serious Central Nervous System (“CNS”) disorders.
Restoring Neurotransmitter Balance in Distinct CNS Conditions
Bionomics has a pipeline of novel, first-in-class, therapeutic candidates targeting ion channels for the treatment of serious central nervous system disorders with a large unmet need. These CNS disorders include mental health disorders and neurological disorders, which impact millions of people.
Our pipeline is further enhanced and accelerated through our partnerships and collaborations, supporting Bionomics early-stage programs.